GALE - SELLAS LIFE SCIENCES GROUP INC

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.26
-0.01 (-5.11%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.28
Open0.29
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.26 - 0.40
52 Week Range0.26 - 0.40
Volume20,365,875
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Why Galena Biopharma Inc’s (NASDAQ:GALE) Investor Composition Impacts Your Returns
    Simply Wall St.2 months ago

    Why Galena Biopharma Inc’s (NASDAQ:GALE) Investor Composition Impacts Your Returns

    I am going to take a deep dive into Galena Biopharma Inc’s (NASDAQ:GALE) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...

  • ACCESSWIRE4 months ago

    Blog Exposure - Galena Biopharma’s Stockholders Approve Business Combination with SELLAS Life Sciences Group

    LONDON, UK / ACCESSWIRE / January 03, 2018 / Active-Investors.com has just released a free research report on Galena Biopharma, Inc. (NASDAQ: GALE ).If you want access to this report all you need to do ...

  • How Does Galena Biopharma Inc (NASDAQ:GALE) Affect Your Portfolio Returns?
    Simply Wall St.4 months ago

    How Does Galena Biopharma Inc (NASDAQ:GALE) Affect Your Portfolio Returns?

    If you are a shareholder in Galena Biopharma Inc’s (NASDAQ:GALE), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Company Update (NASDAQ:GALE): Galena Biopharma Inc Shares Are Racing Up the Market 17%; Here’s Why
    SmarterAnalyst4 months ago

    Company Update (NASDAQ:GALE): Galena Biopharma Inc Shares Are Racing Up the Market 17%; Here’s Why

    In addition to giving a nod to the SELLAS alliance, the GALE board has likewise set into motion a reverse stock split ratio. One proposal, regarding approval of an amendment to Galena’s Certificate of Incorporation to allow the Galena board of directors to approve amendments to Galena’s bylaws, was not approved.

  • Where Galena Biopharma Inc (GALE) Stands In Terms Of Earnings Growth Against Its Industry
    Simply Wall St.5 months ago

    Where Galena Biopharma Inc (GALE) Stands In Terms Of Earnings Growth Against Its Industry

    When Galena Biopharma Inc (NASDAQ:GALE) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...

  • Associated Press5 months ago

    Galena Biopharma reports 3Q loss

    On a per-share basis, the San Ramon, California-based company said it had a loss of 15 cents. In the final minutes of trading on Thursday, the company's shares hit 31 cents. A year ago, they were trading ...

  • PR Newswire6 months ago

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Galena Biopharma, Inc. - GALE

    NEW YORK , Oct. 31, 2017 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...

  • Is Galena Biopharma Inc’s (GALE) Balance Sheet A Threat To Its Future?
    Simply Wall St.6 months ago

    Is Galena Biopharma Inc’s (GALE) Balance Sheet A Threat To Its Future?

    While small-cap stocks, such as Galena Biopharma Inc (NASDAQ:GALE) with its market cap of USD $14.97M, are popular for their explosive growth, investors should also be aware of their balanceRead More...

  • PR Newswire7 months ago

    SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA

    HAMILTON, Bermuda and NEW YORK, Oct. 2, 2017 /PRNewswire/ --  SELLAS Life Sciences Group, Ltd. (SELLAS), a development-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced entry into a Clinical Trial Collaboration and Supply Agreement for the conduct of a combination clinical trial targeting multiple cancer types with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada).  SELLAS' Wilms tumor-1 (WT1)-targeting peptide immunotherapeutic agent, galinpepimut-S, will be administered in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase 1/2 trial enrolling patients in five cancer indications, including both hematologic malignancies and solid tumors.

  • PR Newswire7 months ago

    SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA

    HAMILTON, Bermuda and NEW YORK, Oct. 2, 2017 /PRNewswire/ -- SELLAS Life Sciences Group, Ltd. (SELLAS), a development-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced entry into a Clinical Trial Collaboration and Supply Agreement for the conduct of a combination clinical trial targeting multiple cancer types with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada).  SELLAS' Wilms tumor-1 (WT1)-targeting peptide immunotherapeutic agent, galinpepimut-S, will be administered in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase 1/2 trial enrolling patients in five cancer indications, including both hematologic malignancies and solid tumors.

  • How Does Investing In Galena Biopharma Inc (GALE) Impact Your Portfolio?
    Simply Wall St.7 months ago

    How Does Investing In Galena Biopharma Inc (GALE) Impact Your Portfolio?

    For Galena Biopharma Inc’s (NASDAQ:GALE) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Broadly speaking, thereRead More...

  • Reuters7 months ago

    Galena settles U.S. kickback charges related to opioid drug

    Galena Biopharma Inc will pay more than $7.55 million to resolve charges it paid kickbacks to doctors to induce them to prescribe its opioid-based pain medication Abstral to patients, the U.S. Department of Justice said on Friday. The settlement with Galena comes as federal authorities try to combat an epidemic of opioid abuse, which President Donald Trump last month declared a national emergency.

  • Associated Press8 months ago

    Galena Biopharma reports 2Q loss

    The San Ramon, California-based company said it had a loss of 22 cents per share. Losses, adjusted to account for discontinued operations and non-recurring costs, were 16 cents per share. In the final ...

  • ACCESSWIRE8 months ago

    Featured Company News - Galena Biopharma Announces Merger Agreement with SELLAS Life Sciences Group

    Research Desk Line-up: Blueprint Medicines Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 10, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines ...

  • ACCESSWIRE8 months ago

    Today's Research Reports on Stocks to Watch: Depomed Inc. and Galena Biopharma

    NEW YORK, NY / ACCESSWIRE / August 9, 2017 / Despite Depomed Inc. releasing second quarter EPS that was in line with estimates, the Street still wasn't impressed with the company's loss for the quarter ...

  • Top 10 Penny Stocks To Buy in 2017
    Insider Monkey10 months ago

    Top 10 Penny Stocks To Buy in 2017

    What are the top 10 penny stocks to buy in 2017? Out of thousands of stocks that are trading at price levels below $1.00, it can be hard to identify winning picks, especially since it’s no secret that the companies behind penny stocks may be involved in scams or other shady endeavors that will cause […]